To help treat patients with hormone deficiency, scientists from The Scripps Research Institute have developed a new potential therapy based on immune molecules found in the body of cows, published in the international journal PNAS. In addition, studies have revealed that human hormones and antibodies can be fused to each other, thereby mimicking long stem-like cow antibodies.
Researcher Tao Liu pointed out that we were motivated by a special structure found in nature, so we began to assemble and modify an antibody, expecting it to help human health one day; many people need injections Human growth hormone (hGH) to fight various diseases, such as Turner syndrome (female short stature), low birth weight and other hormone-deficient diseases, but unfortunately the human body will rapidly degrade human growth hormone, sometimes Degraded in 30 minutes.
Therefore, this means that humans must inject human growth hormone daily, which is almost impossible for individuals to achieve; however, antibodies can be maintained in the body for several weeks. In this study, the researchers were found in 2013. Inspired by the class of antibodies, bovine antibodies have a special structure, a circular base plus a longer amino acid stem chain, which is a rotating region at the top of the amino acid stem chain, which the researchers speculate can bind to the pathogen.
Researchers want to know if they can switch on the rotating region of human hormone DNA, such as human growth hormone; to test this hypothesis, researchers use DNA recombination technology to combine human growth hormone with stem-like curly structures from bovine antibodies. Fusion, this fusion process is very stable and can maintain the function of human growth hormone. The next step is to try to create a new type of antibody-hormone molecule, so that this molecule can be used in human therapy, and researchers use humanized resistance. The cancer antibody Herceptin is used as a benchmark antibody in novel therapies.
Subsequently, the researchers used the rat model to detect the antibody-human growth hormone molecule, and the results showed that the human growth hormone-deficient rats can grow normally after receiving the therapy. In fact, the treated rats only need to inject two per week. Secondary fusion antibodies can be grown, while the control group requires daily injection of human growth hormone. According to Dr. Liu, this means that our new therapies require only weekly or monthly injections in humans to treat diseases caused by hormone deficiency.
In order to further examine the function of this novel fusion molecule, the researchers adsorbed the humanized anti-cancer antibody Herceptin® to leptin. The results showed that the antibody-leptin molecule has the same therapeutic effect as natural leptin; Finally, the researchers said that we are currently studying to standardize the treatments applied to the human body, and we hope that the new methods proposed in the later paragraphs can transport large doses of modified human growth hormone molecules in the future to help treat more. The disease patient.